USO 23164

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (CB10A)

Disease Types: CAR-T

Available at:

• Norfolk (Brock Cancer Center)